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Emergence of Metronidazole-Resistant
Bacteroides fragilis, India
To the Editor: Members of the Bacteroides fragilis group are
the most commonly isolated anaerobic pathogens in
humans. Metronidazole has been the drug of choice for
preventing and treating such infections for 40 years.
Although B. fragilis exhibits the broadest spectrum of
recognized resistance to antimicrobial agents among
anaerobes, the worldwide rate of metronidazole resistance
remains low, <5% (1,2). We report here the first metronida-
zole-resistant strain of B. fragilis from India.
A 34-year-old man with myelodysplastic syndrome was
admitted to our hospital with a short history of myalgia,
general malaise, and bleeding gums. Bone marrow exami-
nation showed evidence of severe aplastic anaemia, for
which he was treated with  cyclophosphamide and blood
transfusions. Ceftazidime and amikacin were also adminis-
tered empirically for febrile neutropenia. The patient
remained in the intensive care unit of our medical oncology
ward and was given repeated courses of chemotherapy and
blood transfusions. He also had repeated episodes of febrile
neutropenia, which resolved with a combination of vanco-
mycin, aminoglycosides, and third-generation cephalospor-
in. After 4 months in the hospital, during an episode of
febrile neutropenia, the patient’s condition started to
deteriorate, and high-grade fever developed. Physical
examination showed temperature of 38°C, heart
rate 80/min, blood pressure 100/70 mmHg, and marked
pallor. Laboratory investigations showed a hemoglobin level
of 4g/dL and marked neutropenia (absolute neutrophil count
320/mm3). Liver and renal function test results were within
normal limits. Peripheral blood smears were negative for
malarial parasites. Culture of urine revealed no growth,
and the Widal test was negative. Two blood samples were
collected in Wampole isolator tubes (Wampole Laboratories,
Cranbury, NJ), for isolation of aerobic and anaerobic
bacteria. Subsequently, intravenous antimicrobial therapy
with vancomycin, metronidazole, and ceftazidime was started.
The patient died a day after collection of blood for culture.
Antemortem blood cultures grew Pseudomonas aerugi-
nosa and B. fragilis. The isolate of B. fragilis was identified
by conventional tests and Rap ID ANA II system  (Innovative
Diagnostic System, Norcross, GA). P. aeruginosa was
sensitive to piperacillin but resistant to amikacin, ceftazi-
dime, cefotaxime, and ciprofloxacin. B. fragilis was resis-
tant to metronidazole (MICs, 256 µg/mL) by both standard
broth dilution method and E-test (AB Biodisk, Solne,
Sweden). The isolate was also resistant to cefotaxime and
ceftazidime. However, it was sensitive to chloramphenicol,
clindamycin, and imipenem.
Primary bacteremia caused by anaerobic organisms
accounts for <5% of septicemia in cancer patients (3).
Chemotherapy is a known predisposing factor for anaerobic
bacteremia because it causes gastrointestinal ulceration,
which permits anaerobes to enter circulation (4).
Anaerobic bacteremia is usually polymicrobial in
etiology and has a high death rate (4). In this case, both
bacterial isolates were resistant to the empirical treatment.
Delay in initiating appropriate therapy was perhaps a
major contributor to the patient’s death.
Metronidazole is the drug of choice for empirical
coverage of anaerobic infections. The precise incidence of
resistance to metronidazole in B. fragilis isolates is difficult
to estimate (5), since routine antimicrobial sensitivity
testing of anaerobes is not being done by most laboratories
in the world. Published articles reveal only a few reported
cases of B. fragilis that were resistant to metronida-
zole (6-10). Although the incidence of resistance to penicil-
lin, cephalosporins, and clindamycin is increasing dramati-
cally, no resistance to metronidazole in B. fragilis was found in
some large-scale studies done throughout the world (11,12).
The true incidence of metronidazole resistance in India
too is possibly underestimated since antimicrobial sensitivi-
ty testing is not being done routinely. However, we are
conducting antimicrobial susceptibility testing of all
anaerobic isolates in our institute. In a previous study we
conducted (13), contrary to this report, none of 32 clinical
isolates belonging to the family Bacteroidaceae obtained
over a 5-year period were resistant to metronidazole.
Recently, the anaerobic reference unit in the UK noted
a possible increase in the incidence of metronidazole
resistance in B. fragilis, an observation that would have
major implications for clinical microbiology laboratories, as
well as for prophylactic and treatment regimens (5).
There is now a growing debate whether in vitro suscep-
tibility testing should be performed for all Bacteroides
isolates to guide antimicrobial therapy. The acquisition of
metronidazole resistance by B. fragilis reported here from
India emphasizes the need for a study to assess more accurate-
ly the susceptibilities of clinical isolates of Bacteroides spp.
Diagnostic microbiology laboratories and clinicians
should be aware that the incidence of metronidazole
resistance in clinically significant anaerobes may be
increasing (5). Since antimicrobial resistance in anaerobes
varies from one hospital to another and between different
geographic locations, all hospitals should survey their
sensitivity patterns and report any emerging resistance.
Rama Chaudhry, Purva Mathur,
Benu Dhawan, and Lalit Kumar
All India Institute of Medical Sciences, New Delhi, India
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Proper Nomenclature for the Human
Granulocytic Ehrlichiosis Agent
To the Editor: In their recent article, “Antigenic variations
in vector-borne pathogens,” Barbour and Restrepo discuss
the outer membrane protein components of Anaplasma
marginale and related bacteria (1). Citing a reference by Zhi
et al. (2), they state that Ehrlichia granulocytophila is the
agent of human granulocytic ehrlichiosis (HGE).
The use of new names and combinations not widely
recognized for genera and species lends increasing confu-
sion to a group of bacteria already in taxonomic disarray.
Several other species names have been suggested for the
HGE agent since the initial description of the clinical
illness caused by this agent and the in vitro technique used
to isolate the agent in blood samples (3,4). Both E. phagocy-
tophila and E. equi are genetically nearly identical to the
HGE agent, and the three are probably conspecific. Thus,
most scientists in the field today would support use of the
name Ehrlichia phagocytophila to describe these bacteria.
Recent phylogenetic analyses show that E. phagocyto-
phila strains align into a clade that includes Anaplasma
marginale, the historical precedent in this grouping. Such
phylogenetic analyses, which are also supported by compar-
ative antigenic and biological studies, have resulted in a
proposal for reclassification of several Ehrlichia spp.,
including E. phagocytophila, into the genus Anaplasma (5).
Until a cogent reclassification based on objective criteria is
firmly accepted, the creation and use of new scientific name
combinations for a single bacterium yield clinical and
laboratory confusion and should be avoided.
Johan S. Bakken* and J. Stephen Dumler†
*St. Mary’s Duluth Clinic, Duluth, Minnesota, USA; and
†Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
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Single Nucleotide Polymorphisms in
Mycobacterium tuberculosis Structural Genes
To the Editor: A recent article by Fraser et al. (1) discussed
the frequency of single nucleotide polymorphisms (SNPs) in
two genomes of Mycobacterium tuberculosis, strains H37Rv
(2) and CDC1551 (unpublished). The article contains an
inaccurate representation of our published M. tuberculosis
data on SNP frequency. The authors state that “detailed
comparison of strains H37Rv and CDC1551 indicates a
higher frequency of polymorphism, approximately 1 in
3,000 bp, with approximately half the polymorphism [sic]
occurring in the intergenic regions. In other words, 50% of
the polymorphisms are in 10% of the genome. While this
rate is higher than that suggested (3), it still represents a
lower nucleotide diversity than found in limited compari-
sons from other pathogens.”
On the basis of comparative sequence analysis of eight
M. tuberculosis structural gene loci (open reading frames
[orf]), we initially published an estimated average number
of synonymous substitutions per synonymous site (Ks value)
that indicated that this pathogen had, on average, approxi-
mately 1 synonymous difference per 10,000 synonymous
sites (4). This finding was unexpected given the relatively
large population size of M. tuberculosis and paleopathologic